AMDD ...NEWS JUST OUT
Thursday April 30, 10:00 am Eastern Time
Company Press Release
SOURCE: AMDL, Inc.
AMDL Files for FDA Clearance PyloriProbe(TM) Diagnostic Test
TUSTIN, Calif., April 30 /PRNewswire/ -- AMDL, Inc., (OTC Bulletin Board: AMDD - news) an inventor and marketer of state-of-the art diagnostic kits, today announced it has filed a 510(k) submission with the U.S. Food and Drug Administration requesting clearance to market in the United States its PyloriProbe(TM) diagnostic test for the detection of the bacterium known to cause gastric and duodenal ulcers and, if untreated, stomach cancer.
Helicobacter pylori infection is believed to be the most prevalent disease on earth, impacting almost one of every three people. Available antibiotic treatment can usually rid the stomach of the bacterium.
The AMDL submission follows clinical trials involving 395 patients at medical centers in California, Ohio, Tennessee and Oregon.
AMDL's non-invasive diagnostic test, a direct enzyme immunoassay, determines whether there are antibodies to the bacterium in the patient's blood.
AMDL, headquartered in Tustin, CA, (OTC Bulletin Board: AMDD - news), is also engaged in applying innovative technology to develop novel and improved diagnostic tests for the early detection of cancer. AMDL also markets other high-quality diagnostic tests worldwide.
Except for the historical information contained herein, the matters discussed are forward-looking statements which involve risks and uncertainties, including, but not limited to, economic, competitive, governmental, and technological factors affecting the revenues, operations, markets, products, prices and other factors discussed in the Company's various filings with the Securities and Exchange Commission.
SOURCE: AMDL, Inc.
|
